CELYAD SA/ADR (CYAD) Given Consensus Rating of “Buy” by Brokerages

Share on StockTwits

CELYAD SA/ADR (NASDAQ:CYAD) has been assigned a consensus rating of “Buy” from the seven research firms that are covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $44.20.

CYAD has been the subject of a number of recent analyst reports. William Blair reaffirmed a “buy” rating on shares of CELYAD SA/ADR in a research note on Tuesday, December 4th. HC Wainwright reiterated a “buy” rating and set a $46.00 price objective on shares of CELYAD SA/ADR in a research note on Wednesday, November 21st. Zacks Investment Research upgraded shares of CELYAD SA/ADR from a “hold” rating to a “buy” rating and set a $31.00 price objective for the company in a research note on Thursday, November 15th. Finally, Piper Jaffray Companies reduced their price objective on shares of CELYAD SA/ADR to $51.00 and set an “overweight” rating for the company in a research note on Monday, November 12th.

CYAD traded up $0.10 during trading on Friday, hitting $22.59. The company’s stock had a trading volume of 22,742 shares, compared to its average volume of 9,136. CELYAD SA/ADR has a one year low of $15.36 and a one year high of $48.20. The company has a market capitalization of $223.02 million, a PE ratio of -6.38 and a beta of 1.77.

A number of large investors have recently added to or reduced their stakes in CYAD. Millennium Management LLC purchased a new stake in CELYAD SA/ADR during the 2nd quarter worth approximately $582,000. Victory Capital Management Inc. grew its position in CELYAD SA/ADR by 2.8% during the 3rd quarter. Victory Capital Management Inc. now owns 621,162 shares of the company’s stock worth $16,374,000 after purchasing an additional 17,160 shares during the last quarter. Finally, Wells Fargo & Company MN grew its position in CELYAD SA/ADR by 1,109.0% during the 3rd quarter. Wells Fargo & Company MN now owns 6,045 shares of the company’s stock worth $160,000 after purchasing an additional 5,545 shares during the last quarter. 7.45% of the stock is currently owned by institutional investors.

About CELYAD SA/ADR

Celyad SA, a clinical-stage biopharmaceutical company, focuses on the development of CAR-T cell-based therapies. The company utilizes its expertise in cell engineering to target cancer. Its CAR-T cell platform has the potential to treats a range of solid and hematologic tumors. The company's lead drug product candidate, CYAD-01 (CAR-T NKG2D), has been evaluated in a Phase I clinical trial to assess the safety and clinical activity of multiple administrations of autologous CYAD-01 cells in seven refractory cancers, including five solid tumors, such as colorectal, ovarian, bladder, triple-negative breast, and pancreatic cancers; and two hematological tumors comprising acute myeloid leukemia and multiple myeloma.

Recommended Story: Risk Tolerance and Your Investment Decisions

Analyst Recommendations for CELYAD SA/ADR (NASDAQ:CYAD)

Receive News & Ratings for CELYAD SA/ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CELYAD SA/ADR and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2019 BBNS.